These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 34666670

  • 1. Hsp90 up-regulates PD-L1 to promote HPV-positive cervical cancer via HER2/PI3K/AKT pathway.
    Zeng J, He SL, Li LJ, Wang C.
    Mol Med; 2021 Oct 19; 27(1):130. PubMed ID: 34666670
    [Abstract] [Full Text] [Related]

  • 2. MiR-125 inhibited cervical cancer progression by regulating VEGF and PI3K/AKT signaling pathway.
    Fu K, Zhang L, Liu R, Shi Q, Li X, Wang M.
    World J Surg Oncol; 2020 May 30; 18(1):115. PubMed ID: 32473637
    [Abstract] [Full Text] [Related]

  • 3. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W, Wu QD, Zhang M, Kong YL, Cao PR, Zheng W, Xu JH, Ye M.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):862-71. PubMed ID: 25449780
    [Abstract] [Full Text] [Related]

  • 4. Knockdown of hnRNP A2/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway.
    Shi X, Ran L, Liu Y, Zhong SH, Zhou PP, Liao MX, Fang W.
    Oncol Rep; 2018 Mar 28; 39(3):939-950. PubMed ID: 29328485
    [Abstract] [Full Text] [Related]

  • 5. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.
    Yu W, Hua Y, Qiu H, Hao J, Zou K, Li Z, Hu S, Guo P, Chen M, Sui S, Xiong Y, Li F, Lu J, Guo W, Luo G, Deng W.
    Cell Death Dis; 2020 Jul 06; 11(7):506. PubMed ID: 32632098
    [Abstract] [Full Text] [Related]

  • 6. M2-type tumor-associated macrophages upregulated PD-L1 expression in cervical cancer via the PI3K/AKT pathway.
    Guo F, Kong W, Li D, Zhao G, Anwar M, Xia F, Zhang Y, Ma C, Ma X.
    Eur J Med Res; 2024 Jul 05; 29(1):357. PubMed ID: 38970071
    [Abstract] [Full Text] [Related]

  • 7. Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway.
    Xu J, Xu S, Fang Y, Chen T, Xie X, Lu W.
    IUBMB Life; 2019 Mar 05; 71(3):347-356. PubMed ID: 30536701
    [Abstract] [Full Text] [Related]

  • 8. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
    Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, Baselga J, Rosen N.
    Oncogene; 2010 Jan 21; 29(3):325-34. PubMed ID: 19855434
    [Abstract] [Full Text] [Related]

  • 9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X, Gao A, Zhang F, Yang Z, Wang S, Fang Y, Li J, Wang J, Shi W, Wang L, Zheng Y, Sun Y.
    Theranostics; 2021 Jan 21; 11(7):3392-3416. PubMed ID: 33537094
    [Abstract] [Full Text] [Related]

  • 10. FNDC5 inhibits malignant growth of human cervical cancer cells via restraining PI3K/AKT pathway.
    Li N, Wang XL, Ge R, Wang Y, Tian XL, Zhu GQ, Zhou B.
    J Cell Physiol; 2024 Jun 21; 239(6):e31267. PubMed ID: 38558303
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
    Schulz R, Streller F, Scheel AH, Rüschoff J, Reinert MC, Dobbelstein M, Marchenko ND, Moll UM.
    Cell Death Dis; 2014 Jan 02; 5(1):e980. PubMed ID: 24384723
    [Abstract] [Full Text] [Related]

  • 13. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
    Jiang Y, Yuan Y, Chen M, Li S, Bai J, Zhang Y, Sun Y, Wang G, Xu H, Wang Z, Zheng Y, Nie H.
    Theranostics; 2021 Jan 02; 11(18):9162-9176. PubMed ID: 34522232
    [Abstract] [Full Text] [Related]

  • 14. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
    Dastmalchi N, Hosseinpourfeizi MA, Khojasteh SMB, Baradaran B, Safaralizadeh R.
    Life Sci; 2020 Oct 15; 259():118239. PubMed ID: 32784058
    [Abstract] [Full Text] [Related]

  • 15. ARHGAP17 suppresses tumor progression and up-regulates P21 and P27 expression via inhibiting PI3K/AKT signaling pathway in cervical cancer.
    Guo Q, Xiong Y, Song Y, Hua K, Gao S.
    Gene; 2019 Apr 15; 692():9-16. PubMed ID: 30641218
    [Abstract] [Full Text] [Related]

  • 16. Human papillomavirus 16 E6/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142-5p/PD-L1 axis.
    Ling J, Sun Q, Tian Q, Shi H, Yang H, Ren J.
    Arch Biochem Biophys; 2022 Nov 30; 731():109449. PubMed ID: 36288761
    [Abstract] [Full Text] [Related]

  • 17. Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients.
    Yang-Chun F, Zhen-Zhen C, Yan-Chun H, Xiu-Min M.
    Medicine (Baltimore); 2017 Jun 30; 96(25):e7270. PubMed ID: 28640134
    [Abstract] [Full Text] [Related]

  • 18. Human papillomavirus type 16 E7 oncoprotein-induced upregulation of lysine-specific demethylase 5A promotes cervical cancer progression by regulating the microRNA-424-5p/suppressor of zeste 12 pathway.
    Liu J, Zhao H, Zhang Q, Shi Z, Zhang Y, Zhao L, Ren Y, Ou R, Xu Y.
    Exp Cell Res; 2020 Nov 01; 396(1):112277. PubMed ID: 32918895
    [Abstract] [Full Text] [Related]

  • 19. Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma.
    Ueno S, Sudo T, Oka N, Wakahashi S, Yamaguchi S, Fujiwara K, Mikami Y, Nishimura R.
    Int J Gynecol Cancer; 2013 Jul 01; 23(6):1084-91. PubMed ID: 23792604
    [Abstract] [Full Text] [Related]

  • 20. Period circadian regulator 2 suppresses drug resistance to cisplatin by PI3K/AKT pathway and improves chronochemotherapeutic efficacy in cervical cancer.
    Wang Z, Li F, He S, Zhao L, Wang F.
    Gene; 2022 Jan 30; 809():146003. PubMed ID: 34648915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.